Verrica Pharmaceuticals (NASDAQ:VRCA) has priced a securities offering to raise around $42M.
The offering comprises 44.96M shares of VRCA common stock, in lieu of common stock to certain investors that so choose, and pre-funded warrants to purchase 2.24M shares, and in either case, accompanying warrants.
The Series A warrants, to purchase 23.6M shares, are exercisable at $1.0680 per share. The Series B warrant, to purchase 23.6M shares, are exercisable at $1.3350 per share.
The combined public offering price is $0.89 per share of common stock and accompanying Series A and Series B warrants.
Verrica (VRCA) also granted the underwriter a 30-day option to purchase up to 7.08M additional shares of the company’s common stock and/or Series A warrants to purchase up to 3.54M additional shares and Series B warrants to purchase up to 3.54M additional shares.
The gross proceeds from the offering are expected to be approximately $42M.
VRCA shares were down around 10% Thursday premarket.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.